252 related articles for article (PubMed ID: 33492425)
21. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
22. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
[TBL] [Abstract][Full Text] [Related]
23. Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening.
Takahashi T
World J Urol; 2024 Mar; 42(1):167. PubMed ID: 38492072
[No Abstract] [Full Text] [Related]
24. Early detection, PSA screening, and management of overdiagnosis.
Borza T; Konijeti R; Kibel AS
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
[TBL] [Abstract][Full Text] [Related]
25. Summary statement on screening for prostate cancer in Europe.
Heijnsdijk EAM; Bangma CH; Borràs JM; de Carvalho TM; Castells X; Eklund M; Espinàs JA; Graefen M; Grönberg H; Lansdorp-Vogelaar I; Leeuwen PJV; Nelen V; Recker F; Roobol MJ; Vandenbulcke P; de Koning HJ
Int J Cancer; 2018 Feb; 142(4):741-746. PubMed ID: 29023685
[TBL] [Abstract][Full Text] [Related]
26. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
27. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
28. Active surveillance for prostate cancer: overview and update.
Klotz L
Curr Treat Options Oncol; 2013 Mar; 14(1):97-108. PubMed ID: 23318986
[TBL] [Abstract][Full Text] [Related]
29. The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment.
Hewitt K; Son J; Glencer A; Borowsky AD; Cooperberg MR; Esserman LJ
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2463-2474. PubMed ID: 33033145
[TBL] [Abstract][Full Text] [Related]
30. [PSA screening and molecular markers].
Lakes J; Arsov C
Urologe A; 2019 May; 58(5):486-493. PubMed ID: 30874831
[TBL] [Abstract][Full Text] [Related]
31. Update on screening in prostate cancer based on recent clinical trials.
Sciarra A; Cattarino S; Gentilucci A; Salciccia S; Alfarone A; Mariotti G; Innocenzi M; Gentile V
Rev Recent Clin Trials; 2011 Jan; 6(1):7-15. PubMed ID: 20868347
[TBL] [Abstract][Full Text] [Related]
32. [Intelligent early prostate cancer detection in 2021: more benefit than harm].
Westhoff N; von Hardenberg J; Michel MS
Urologe A; 2021 May; 60(5):602-609. PubMed ID: 33881554
[TBL] [Abstract][Full Text] [Related]
33. How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis?
Rahbar H; McDonald ES; Lee JM; Partridge SC; Lee CI
Acad Radiol; 2016 Jun; 23(6):768-73. PubMed ID: 27017136
[TBL] [Abstract][Full Text] [Related]
34. [Overdiagnosis in mammography screening for breast cancer].
Huang YB; Yang L; Song FJ; Chen KX
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Nov; 38(11):1574-1578. PubMed ID: 29141352
[TBL] [Abstract][Full Text] [Related]
35. Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?
Rich NE; Singal AG
Hepatology; 2022 Mar; 75(3):740-753. PubMed ID: 34923659
[TBL] [Abstract][Full Text] [Related]
36. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.
Lowenstein LM; Basourakos SP; Williams MD; Troncoso P; Gregg JR; Thompson TC; Kim J
Nat Rev Clin Oncol; 2019 Mar; 16(3):168-184. PubMed ID: 30413793
[TBL] [Abstract][Full Text] [Related]
37. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
Wheeler DC; Szymanski KM; Black A; Nelson DE
BMC Cancer; 2011 Apr; 11():148. PubMed ID: 21510865
[TBL] [Abstract][Full Text] [Related]
38. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
39. Current Issues in the Overdiagnosis and Overtreatment of Breast Cancer.
Monticciolo DL; Helvie MA; Hendrick RE
AJR Am J Roentgenol; 2018 Feb; 210(2):285-291. PubMed ID: 29091010
[TBL] [Abstract][Full Text] [Related]
40. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
